Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Coombs

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Blood|June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trialLindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Haematologica|July 16, 2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemiaCatherine C Coombs, David A Sallman, Sean M Devlin, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Transplantation and Cellular Therapy|June 13, 2025
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Blood|June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trialLindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced MalignanciesGerald Falchook, Seth Rosen, Patricia LoRusso, et al.
Haematologica|July 16, 2016
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemiaCatherine C Coombs, David A Sallman, Sean M Devlin, et al.
Acta Haematologica|June 2, 2024
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell MalignanciesLindsey E Roeker, Catherine C Coombs, Nirav N Shah, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Blood Cancer Discovery|November 15, 2021
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaJoshua F Zeidner, Benjamin G Vincent, Anastasia Ivanova, et al.
Journal of Geriatric Oncology|June 17, 2026
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi settingPaolo Ghia, Davide Rossi, Emmanuelle Ferrant, et al.
Transplantation and Cellular Therapy|June 13, 2025
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, et al.
British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.
Pageof 18